Sunday, February 28, 2016

6:00 p.m.-7:00 p.m.	**Opening Keynote Session** Plaza D-F **Session Chair: Karen E. Knudsen,** Thomas Jefferson University Kimmel Cancer Center, Philadelphia, PA
6:00 p.m.-6:05 p.m.	Welcome
6:05 p.m.-7:00 p.m.	Keynote Address: New Insights into Quiescence Control **David M. Livingston,** Dana-Farber Cancer Institute, Boston, MA
7:00 p.m.-9:00 p.m.	**Opening Reception** Plaza G-H

Monday, February 29, 2016

7:30 a.m.-8:30 a.m.	**Breakfast and Roundtable Discussions** Plaza G-H
8:30 a.m.-10:30 a.m.	**Plenary Session 1 G1 Advances: Novel Insights into G1 CDK/cyclins** Plaza D-F **Session Chair: Manuel Serrano,** Spanish National Cancer Center (CNIO), Madrid, Spain
8:30 a.m.-9:00 a.m.	Neomorphic functions of cyclin D1 during neoplastic development **J. Alan Diehl,** Medical University of South Carolina, Charleston, SC
9:00 a.m.-9:30 a.m.	Identification of cell cycle-regulating microRNAs **Peter Sicinski**, Dana-Farber Cancer Institute, Boston, MA
9:30 a.m.-10:00 a.m.	The Targeting of CDK4/6: Have we gone full circle? **Gary K. Schwartz**, Columbia University Irving Comprehensive Cancer Center, New York, NY
10:00 a.m.-10:15 a.m.	Therapeutic targeting of cdk4 in bladder cancer **Jesus Paramio**, Biomedical Research Institute University Hospital, Madrid, Spain
10:15 a.m.-10:30 a.m.	Targeting the Brk:p27:cdk4 axis in Breast Cancer **Stacy Blain**, SUNY Downstate Medical Center, Brooklyn, NY
10:30 a.m.-11:00 a.m.	**Break** Plaza D-F Lobby

11:00 a.m.-1:00 p.m. **Plenary Session 2 Targeting CDK/cyclins: Hormone Dependent Cancers and Beyond**
Plaza D-F
Session Chair: Helen Piwnica-Worms,
UT MD Anderson Cancer Center, Houston, TX

11:00 a.m.-11:30 a.m. Title to be announced
Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA

11:30 a.m.-12:00 p.m. Co-targeting cell cycle and androgen signaling to personalize therapy for hormone dependent prostate cancer
Maha H. Hussain, University of Michigan Medical School, Ann Arbor, MI

12:00 p.m.-12:30 p.m. Targeting the cyclin D-CDK4/6 pathway for cancer therapy
Robert T. Abraham, Pfizer Pharmaceuticals, San Diego, CA
(Not eligible for CME credit)

12:30 p.m.-1:00 p.m. Reprogramming human cancer cells in CDK4/6 inhibitor therapy
Selina Chen-Kiang, Weill Cornell Medical College of Cornell University, New York, NY

1:00 p.m.-3:30 p.m. **Poster Session A and Lunch**
Plaza G-H

3:30 p.m.-5:30 p.m. **Plenary Session 3 Getting out of Cycle: G0 and Senescence**
Plaza D-F
Session Chair: Charles J. Sherr,
St. Jude Children's Research Hospital, Memphis, TN

3:30 p.m.-4:00 p.m. A drug delivery method selective for senescent cells
Manuel Serrano, Spanish National Cancer Center (CNIO), Madrid, Spain

4:00 p.m.-4:30 p.m. The senescence response – yin and yang
Judith Campisi, Buck Institute for Research on Aging, Novato, CA

4:30 p.m.-5:00 p.m. Transient CDK4/6 inhibition protects hematopoietic progenitors from chemotherapy-induced exhaustion
Norman E. Sharpless, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC

5:00 p.m.-5:15 p.m. Extended inhibition of CDK4/6 inhibits mTORC1 signaling and induces therapeutic senescence in vemurafenib resistant melanoma
Akihiro Yoshida, Medical University of South Carolina, Charleston, SC

5:15 p.m.-5:30 p.m. Characterizing the sequence of cell-cycle events during proliferation and quiescence
Sabrina Spencer, University of Colorado-Boulder, Boulder, CO

Tuesday, March 1, 2016

7:30 a.m.-8:30 a.m. **Breakfast and Roundtable Discussions**
Plaza G-H

8:30 a.m.-10:30 a.m. **Plenary Session 4 Rb Bench to Bedside: Novel Functions and Clinical Implications**
Plaza D-F
Session Chair: Jacqueline A. Lees,
MIT Koch Institute for Integrative Cancer Research, Cambridge, MA

8:30 a.m.-9:00 a.m.	Targeting the cell cycle in pediatric solid tumors **Michael A. Dyer**, St. Jude Children's Research Hospital, Memphis, TN
9:00 a.m.-9:30 a.m.	Modeling RB mutant human cancers in mice to identify novel therapeutic targets **Julien Sage,** Stanford University School of Medicine, Stanford, CA
9:30 a.m.-10:00 a.m.	Interplay of the RB axis with hormone signaling: Mechanisms and novel therapeutic strategies **Karen E. Knudsen,** Thomas Jefferson University Kimmel Cancer Center, Philadelphia, PA
10:00 a.m.-10:15 a.m.	RB localizes to DNA double strand breaks and promotes DNA end resection and homologous recombination through the recruitment of SWI/SNF complex **Renier Velez-Cruz**, The University of Texas MD Anderson Cancer Center, Smithville, TX
10:15 a.m.-10:30 a.m.	Sox2 functions as a critical tumor suppressor in Rb loss initiated tumors **Michael Kareta**, Stanford University, Stanford, CA
10:30 a.m.-11:00 a.m.	**Break** Plaza D-F Lobby
11:00 a.m.-1:00 p.m.	**Plenary Session 5 E2F Family Functions: Alterations and Consequences** Plaza D-F **Session Chair: Peter Sicinski,** Dana-Farber Cancer Institute, Boston, MA
11:00 a.m.-11:30 a.m.	The consequences of pRb inactivation: insights from a proteomic analysis of Rb loss **Nicholas Dyson**, Massachusetts General Hospital Cancer Center, Charlestown, MA
11:30 a.m.-12:00 p.m.	Breaking the balance between E2F Activators and Atypical Repressors: Consequences to Development and Cancer **Gustavo W. Leone**, Ohio State University Comprehensive Cancer Center, Columbus, OH
12:00 p.m.-12:30 p.m.	Title to be announced **Jacqueline A. Lees**, MIT Koch Institute for Integrative Cancer Research, Cambridge, MA
12:30 p.m.-12:45 p.m.	Recruitment of Pontin/Reptin by E2F1 amplifies E2F transcriptional response during cancer progression **Patrick Viatour**, Children's Hospital of Philadelphia, Philadelphia, PA
12:45 p.m.-1:00 p.m.	RB loss elicits extensive re-programming of AR and E2F1 in prostate cancer **Christopher McNair**, Thomas Jefferson University, Philadelphia, PA
1:00 p.m.-3:00 p.m.	**Lunch (on own)**

3:00 p.m.-5:00 p.m. **Plenary Session 6 Replication Stress and DNA Damage Response**
Plaza D-F
Session Chair: Caroline Dive,
CRUK Manchester Institute, Manchester, UK

3:00 p.m.-3:30 p.m. Functional analysis of mammalian Polθ reveals its role in double-strand break repair
Agnel J. Sfeir, New York University Langone Medical Center, New York, NY

3:30 p.m.-4:00 p.m. Mechanisms of alternative telomere recombination
Roger A. Greenberg, University of Pennsylvania, Philadelphia, PA

4:00 p.m.-4:30p.m. Exploiting CDK2-driven replication stress to repurpose cancer chemotherapy
Bruce Clurman, Fred Hutchinson Cancer Research Center, Seattle, WA

4:30 p.m.-4:45 p.m. c-MYC preserves genomic integrity during DNA replication: a paradigm shift of c-MYC
Alpana Kumari, Augusta University, Augusta, GA

4:45 p.m.-5:00 p.m. Exploiting the G2-M cell cycle checkpoint dependency in small cell lung cancer (SCLC) using pharmacological inhibitors of CHK1 and WEE1
Triparna Sen, UT MD Anderson Cancer Center, Houston, TX

5:00 p.m.-5:15 p.m. **Break**
Plaza D-F Lobby

5:15 p.m.-6:15 p.m. **Keynote Address**
Plaza D-F
Session Chair: J. Alan Diehl,
Medical University of South Carolina, Charleston, SC

Mitogenic Signaling and the RB/p53 Network
Charles J. Sherr, St. Jude Children's Research Hospital, Memphis, TN

6:15 p.m.-8:30 p.m. **Poster Session B and Reception**
Plaza G-H

Wednesday, March 2, 2016

7:30 a.m.-8:30 a.m. **Breakfast and Roundtable Discussions**
Plaza G

8:30 a.m.-10:45 a.m. **Plenary Session 7 Managing G2/M Control**
Plaza D-F
Session Chair: J. Alan Diehl,
Medical University of South Carolina, Charleston, SC

8:30 a.m.-9:00 a.m. Circulating tumour cell derived explant models to study the effects of cell cycle targeted drugs in small cell lung cancer
Caroline Dive, CRUK Manchester Institute, Manchester, UK

9:00 a.m.-9:30 a.m. Cyclin A2 controls genome stability through CDK-dependent and independent mechanisms
Jan M. Van Deursen, Mayo Clinic, Rochester, MN

9:30 a.m.-10:00 a.m. Checkpoint signaling and targeting in cancer cells
Helen Piwnica-Worms, UT MD Anderson Cancer Center, Houston, TX

10:00 a.m.-10:15 a.m. APC/CCdh1 maintains primordial follicles, germinal vesicle arrest and ensures balanced segregation of chromosomes by enabling removal of Shugoshin-2 from chromosomes arms
Ahmed Rattani, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA

10:15 a.m.-10:30 a.m. Genome-wide CRISPR-Cas9 screens reveal loss of redundancy between PKMYT1 and WEE1 in patient-derived Glioblastoma stem-like cells
Patrick Paddison, Fred Hutchinson Cancer Research Center, Seattle, WA

10:30 a.m.-10:45 a.m. Germ-line mutations in CDC20 result in familial cancers via deregulation of the cell cycle
Ester Castellsague, McGill University, Montreal, Canada

10:45 a.m.-11:15 a.m. **Break**
Plaza D-F Lobby

11:15 a.m.-1:00 p.m. **Plenary Session 8 Derailed by Infection: Viral-mediated Cell Cycle Dysfunction**
Plaza D-F
Session Chair: Julien Sage,
Stanford University School of Medicine, Stanford, CA

11:15 a.m.-11:45 a.m. Merkel cell polyomavirus Small T antigen recruits MYCL to the TRRAP-p400 complex to promote oncogenesis and re-programming
James A. DeCaprio, Dana-Farber Cancer Institute, Boston, MA

11:45 a.m.-12:15 p.m. Title to be announced
Maura Gillison, Ohio State University Comprehensive Cancer Center, Columbus, OH

12:15 p.m.-12:45 p.m. Perturbation of host cellular regulatory networks by human papillomaviruses
Karl Munger, Tufts University School of Medicine, Boston, MA

12:45 p.m.-1:00 p.m. Real-time in vivo image-guided cell-cycle perturbation to increase tumor chemosensitivity
Shuya Yano, Okayama University, Okayama, Japan
(Not eligible for CME credit)

1:00 p.m.-1:15p.m. **Closing Remarks and Departure**
Plaza D-F